{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3830","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"1303"}],"units":"Participants"}],"description":"Objective 5: To describe the distribution of chemotherapy dose delays and reductions, surgery delays and cancellations, radiotherapy delays, dose reductions, and cancellations, and mortality (GCSF-related; FN-related; cancer-related; not related to GCSF, FN, or cancer; all-cause); and estimate the time-to-event for such events over the course of EP2006 treatment.\n\nTable presents number of patients who had a cancer-related death by any/no CIN/FN-related chemotherapy disturbance\n\nCIN: chemotherapy-induced neutropenia; FN: febrile neutropenia","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN who had any CIN/FN-related chemotherapy disturbance","id":"OG000","title":"EP2006: Any CIN/FN-related Chemotherapy Disturbance"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN who had no CIN/FN-related chemotherapy disturbance","id":"OG001","title":"EP2006: No CIN/FN-related Chemotherapy Disturbance"}],"paramType":"NUMBER","populationDescription":"Evaluable sample by any/no CIN/FN-related chemotherapy disturbance with data","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Number of Participants With Cancer-related Mortality by Any CIN/FN-related Chemotherapy Disturbance","type":"PRIMARY","unitOfMeasure":"participants"}